Advertisement

Der Hautarzt

, 65:590 | Cite as

Kutanes Plattenepithelkarzinom unter Berücksichtigung besonderer Patientengruppen

  • U. HillenEmail author
  • M. Ulrich
  • M. Alter
  • J.C. Becker
  • R. Gutzmer
  • U. Leiter
  • A. Lonsdorf
  • A. Messerschmidt
  • C. Ulrich
Leitthema

Zusammenfassung

Die malignen epithelialen Tumore haben eine steigende Inzidenz. Das kutane Plattenepithelkarzinom (PEK) ist ein Tumor des höheren Lebensalters. Aufgrund der steigenden Lebenserwartung ist mit einer zunehmenden Häufigkeit der Erkrankung zu rechnen. In der Regel hat das PEK eine gute Prognose. Die Therapie besteht in der mikroskopisch kontrollierten Chirurgie des Tumors. Fortgeschrittene und metastasierte PEK stellen dagegen eine therapeutische Herausforderung dar. Bei Patienten mit Lymphknotenmetastasen liegen die 10-Jahres-Überlebensraten unter 20 %, bei Patienten mit Fernmetastasen unter 10 %. Immunsupprimierte haben ein erhöhtes Metastasierungsrisiko. Der Beitrag gibt eine Übersicht über das PEK unter besonderer Berücksichtigung der Patientengruppen, die einem erhöhten Risiko ausgesetzt sind.

Schlüsselwörter

Maligne epitheliale Tumore Therapie Lymphknotenmetastasen Fernmetastasen Immunsuppression 

Cutaneous squamous cell carcinoma: A review with consideration of special patient groups

Abstract

The incidence of non-melanoma skin cancer (NMSC) is increasing. Squamous cell carcinoma of the skin (SCC) is a tumor of the elderly. Due to the increasing life expectancy, SCC will become more and more frequent in the future. Generally SCC has a favorable prognosis. Standard therapy is microscopically- controlled excision. Therapy of advanced and metastatic SCC is still challenging. Patients with regional lymph node metastasis have ten-year survival rates less than 20 %; patients with distant metastases less than 10 %. Immunosuppression has been shown to be one of the key prognostic factors for metastasis. The article reviews SCC and focusses on patients being at risk for an unfavorable course.

Keywords

Non-melanoma skin cancer Therapy Lymph node metastasis Distant metastases Immunosuppression 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Ulrich: Vortragshonorare, Studien und Beratung: Almirall, Leo. R. Gutzmer: Vortragshonorare, medizinische Beratung, Studien, Projektunterstützung von Leo, Almirall, Pfizer, Novartis, MerckSerono. U. Leiter: Vortragshonorare: Roche, Meda, Novartis. A.S. Lonsdorf: Vortragshonorare, medizinische Beratung: Galderma Laboratories GmbH. C. Ulrich: Vortragshonorare, medizinische Beratung und Studien von Galderma, Meda, Leo, Urgo, Almirall, Roche, Pfizer, Novartis, 3M. U. Hillen, M. Alter, J.C. Becker und A. Messerschmidt geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 166:1069–1080PubMedCrossRefGoogle Scholar
  2. 2.
    Katalinic A, Kunze U, Schafer T (2003) Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 149:1200–1206PubMedCrossRefGoogle Scholar
  3. 3.
    Alam M, Ratner D (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344:975–983PubMedCrossRefGoogle Scholar
  4. 4.
    Hollestein LM, Vries E de, Nijsten T (2012) Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989–2008. Eur J Cancer 48:2046–2053PubMedCrossRefGoogle Scholar
  5. 5.
    Kraywinkel K, Wolf U, Katalinic A (2012) Hautkrebs – Epidemiologie und Früherkennung. UMID, Umwelt und Mensch-Informationsdienst. Ausgabe 2:30–34Google Scholar
  6. 6.
    Elmets CA, Athar M (2013) Milestones in photocarcinogenesis. J Invest Dermatol 133:E13–E17PubMedCrossRefGoogle Scholar
  7. 7.
    Schwarz T (2010) The dark and the sunny sides of UVR-induced immunosuppression: photoimmunology revisited. J Invest Dermatol 130:49–54PubMedCrossRefGoogle Scholar
  8. 8.
    Nakazawa H, English D, Randell PL et al (1994) UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci U S A 91:360–364PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Ratushny V, Gober MD, Hick R et al (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122:464–472PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Griewank KG, Murali R, Schilling B et al (2013) TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One 8:e80354PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Bundeministerium für Arbeit und Soziales (2013) Empfehlung des Ärztlichen Sachverständigenbeirats „Berufskrankheiten“. Gem Ministerialbl 64:671–693Google Scholar
  12. 12.
    Rangwala S, Tsai KY (2011) Roles of the immune system in skin cancer. Br J Dermatol 165:953–965PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Mehrany K, Weenig RH, Lee KK et al (2005) Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol 53:1067–1071PubMedCrossRefGoogle Scholar
  14. 14.
    Lott DG, Manz R, Koch C, Lorenz RR (2010) Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 90:683–687PubMedCrossRefGoogle Scholar
  15. 15.
    Weedon D, Marks R, Kao GF, Harwood CA (2006) Keratinocytic tumors. In: LeBoit PE, Burg G, Weedon D, Sarasin A (Hrsg) World health organization classification of tumours. IARC Press, LyonGoogle Scholar
  16. 16.
    Farasat S, Yu SS, Neel VA et al (2011) A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 64:1051–1059PubMedCrossRefGoogle Scholar
  17. 17.
    Karia PS, Jambusaria-Pahlajani A, Harrington DP et al (2014) Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 32:327–334PubMedCrossRefGoogle Scholar
  18. 18.
    Breuninger H, Brantsch K, Eigentler T, Hafner HM (2012) Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges 10:579–586PubMedGoogle Scholar
  19. 19.
    Brantsch KD, Meisner C, Schonfisch B et al (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9:713–720PubMedCrossRefGoogle Scholar
  20. 20.
    Schmults CD, Karia PS, Carter JB et al (2013) Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 149:541–547PubMedCrossRefGoogle Scholar
  21. 21.
    Wittekind C, Meyer H (Hrsg) (2010) TNM Klassifikation maligner Tumore. Wiley-VCH, WeinheimGoogle Scholar
  22. 22.
    Clayman GL, Lee JJ, Holsinger FC et al (2005) Mortality risk from squamous cell skin cancer. J Clin Oncol 23:759–765PubMedCrossRefGoogle Scholar
  23. 23.
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4:905–913PubMedCrossRefGoogle Scholar
  24. 24.
    Na R, Grulich AE, Meagher NS et al (2013) Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. Am J Transplant 13:174–183PubMedCrossRefGoogle Scholar
  25. 25.
    Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65:263–279 (quiz 280)PubMedCrossRefGoogle Scholar
  26. 26.
    Wisgerhof HC, Edelbroek JR, Fijter JW de et al (2010) Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 89:1231–1238PubMedCrossRefGoogle Scholar
  27. 27.
    Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348:1681–1691PubMedCrossRefGoogle Scholar
  28. 28.
    Greene MH, Hoover RN, Fraumeni JF Jr (1978) Subsequent cancer in patients with chronic lymphocytic leukemia – a possible immunologic mechanism. J Natl Cancer Inst 61:337–340PubMedGoogle Scholar
  29. 29.
    Beiggi S, Johnston JB, Seftel MD et al (2013) Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 109:1287–1290PubMedCrossRefGoogle Scholar
  30. 30.
    Mehrany K, Weenig RH, Pittelkow MR et al (2005) High recurrence rates of squamous cell carcinoma after Mohs‘ surgery in patients with chronic lymphocytic leukemia. Dermatol Surg 31:38–42 (discussion 42)PubMedCrossRefGoogle Scholar
  31. 31.
    Royle JA, Baade PD, Joske D et al (2011) Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer 105:1076–1081PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Long MD, Martin CF, Pipkin CA et al (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143:390–399PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Setshedi M, Epstein D, Winter TA et al (2012) Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 27:385–389PubMedCrossRefGoogle Scholar
  34. 34.
    Singh H, Nugent Z, Demers AA, Bernstein CN (2011) Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 141:1612–1620PubMedCrossRefGoogle Scholar
  35. 35.
    Pedersen N, Duricova D, Elkjaer M et al (2010) Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 105:1480–1487PubMedCrossRefGoogle Scholar
  36. 36.
    Curtis JR, Jain A, Askling J et al (2010) A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 40:2–14PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Mercer LK, Green AC, Galloway JB et al (2012) The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71:869–874PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Stern RS, PUVA Follow-up Study (2012) The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 66:553–562PubMedCrossRefGoogle Scholar
  39. 39.
    Pouplard C, Brenaut E, Horreau C et al (2013) Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 27(Suppl 3):36–46PubMedCrossRefGoogle Scholar
  40. 40.
    Brewer JD, Hoverson Schott AR, Roenigk RK (2011) Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature. Int J Dermatol 50:1555–1559PubMedCrossRefGoogle Scholar
  41. 41.
    Young L, Czarnecki D (2012) The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 53:57–60PubMedCrossRefGoogle Scholar
  42. 42.
    Di Lernia V, Ricci C (2011) Cutaneous malignancies during treatment with efalizumab and infliximab: when temporal relationship does not mean causality. J Dermatolog Treat 22:229–232CrossRefGoogle Scholar
  43. 43.
    Breuninger H, Eigentler T, Bootz F et al (2013) Brief S2k guidelines – cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 11:37–45, 39–47PubMedCrossRefGoogle Scholar
  44. 44.
    Bonerandi JJ, Beauvillain C, Caquant L et al (2011) Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol 25(Suppl 5):1–51PubMedCrossRefGoogle Scholar
  45. 45.
    National Comprehensive Cancer Network (2014) Basal cell and squamous cell skin cancers. NCCN clinical practice guidelines in oncology. http://www.nccn.orgGoogle Scholar
  46. 46.
    Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP (1997) Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer 79:915–919PubMedCrossRefGoogle Scholar
  47. 47.
    Sadek H, Azli N, Wendling JL et al (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66:1692–1696PubMedCrossRefGoogle Scholar
  48. 48.
    Grau JJ, Caballero M, Verger E et al (2009) Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 129:1294–1299PubMedCrossRefGoogle Scholar
  49. 49.
    Hitt R, Irigoyen A, Cortes-Funes H et al (2012) Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23:1016–1022PubMedCrossRefGoogle Scholar
  50. 50.
    Maubec E, Petrow P, Scheer-Senyarich I et al (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419–3426PubMedCrossRefGoogle Scholar
  51. 51.
    Lewis CM, Glisson BS, Feng L et al (2012) A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18:1435–1446PubMedCrossRefGoogle Scholar
  52. 52.
    Mecca C, Ponzetti A, Caliendo V et al (2012) Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 22:758–761PubMedGoogle Scholar
  53. 53.
    Gutierrez-Dalmau A, Revuelta I, Ferrer B et al (2010) Distinct immunohistochemical phenotype of nonmelanoma skin cancers between renal transplant and immunocompetent populations. Transplantation 90:986–992PubMedCrossRefGoogle Scholar
  54. 54.
    Euvrard S, Morelon E, Rostaing L et al (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339PubMedCrossRefGoogle Scholar
  55. 55.
    Hillen U, Griewank K, Sommerwerck U et al (2013) Tumor regression and sirolimus-based therapy in lung transplantation. J Heart Lung Transplant 32:938–939PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • U. Hillen
    • 1
    Email author
  • M. Ulrich
    • 2
    • 8
  • M. Alter
    • 3
  • J.C. Becker
    • 4
  • R. Gutzmer
    • 4
  • U. Leiter
    • 5
  • A. Lonsdorf
    • 6
  • A. Messerschmidt
    • 7
  • C. Ulrich
    • 8
  1. 1.Klinik für DermatologieUniversitätsklinikum Essen, Westdeutsches Tumorzentrum, Universität Duisburg-EssenEssenDeutschland
  2. 2.Dermatologie am RegierungsviertelBerlinDeutschland
  3. 3.Allgemeine DermatologieMedizinische Universität GrazGrazÖsterreich
  4. 4.Klinik für Dermatologie, Allergologie und VenerologieMedizinische Hochschule HannoverHannoverDeutschland
  5. 5.Zentrum für Dermato-Onkologie, Universitäts-HautklinikEberhard-Karls-Universität TübingenTübingenDeutschland
  6. 6.Universitäts-HautklinikRuprecht-Karls-Universität HeidelbergHeidelbergDeutschland
  7. 7.Klinik für Dermatologie, Allergologie und VenerologieUniversitätsklinikum FrankfurtFrankfurt am MainDeutschland
  8. 8.Klinik für Dermatologie, Venerologie und Allergologie, Hauttumor CentrumCharité Universitätsmedizin Berlin, Charité Campus MitteBerlinDeutschland

Personalised recommendations